<SEC-DOCUMENT>0001193125-21-319497.txt : 20211104
<SEC-HEADER>0001193125-21-319497.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104091033
ACCESSION NUMBER:		0001193125-21-319497
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20211104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Magenta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001690585
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38541
		FILM NUMBER:		211378454

	BUSINESS ADDRESS:	
		STREET 1:		100 TECHNOLOGY SQUARE
		STREET 2:		5TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-201-2700

	MAIL ADDRESS:	
		STREET 1:		100 TECHNOLOGY SQUARE
		STREET 2:		5TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d231816d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgta="http://www.magentatx.com/20211104" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-11-04_to_2021-11-04">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-11-04_to_2021-11-04">0001690585</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="mgta-20211104.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-11-04_to_2021-11-04"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001690585</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-04</xbrli:startDate> <xbrli:endDate>2021-11-04</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-11-04_to_2021-11-04">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt:datemonthdayyearen">November 4, 2021</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-11-04_to_2021-11-04">MAGENTA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-11-04_to_2021-11-04">001-38541</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-11-04_to_2021-11-04">81-0724163</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-11-04_to_2021-11-04">100 Technology Square</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-11-04_to_2021-11-04">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-11-04_to_2021-11-04">02139</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-11-04_to_2021-11-04">(857)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-11-04_to_2021-11-04">242-0170</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the <span style="white-space:nowrap">Form&#160;8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to <span style="white-space:nowrap">Rule&#160;14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to <span style="white-space:nowrap">Rule&#160;14d-2(b)&#160;under</span> the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to <span style="white-space:nowrap">Rule&#160;13e-4(c)&#160;under</span> the Exchange Act (17 CFR <span style="white-space:nowrap">240.13d-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-11-04_to_2021-11-04">Common Stock, $0.001 Par Value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-11-04_to_2021-11-04">MGTA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2021-11-04_to_2021-11-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;4, 2021, Magenta Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended September&#160;30, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit&#160;99.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02 of this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> (including Exhibit&#160;99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;4, 2021, the Company announced upcoming data presentations at the 2021 American Society of Hematology (&#8220;ASH&#8221;) Annual Meeting. The full text of the press release issued in connection with the announcement is filed as Exhibit&#160;99.2 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&#160;Exhibits: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exhibit 99.1 relating to Item 2.02 shall be deemed furnished, and not filed. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d231816dex991.htm">Press Release dated November&#160;4, 2021 (earnings release). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d231816dex992.htm">Press Release dated November&#160;4, 2021 (ASH Annual Meeting updates). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:10%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:89%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">MAGENTA THERAPEUTICS,&#160;INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">November&#160;4, 2021</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Mahoney</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial and Operating Officer</td></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d231816dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g231816g1104044249813.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Magenta Therapeutics Reports Third Quarter Financial Results </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and Program Highlights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Positive topline clinical data from all patients in an investigator-initiated Phase 2 clinical trial evaluating stem cell
mobilization and transplant engraftment using <FONT STYLE="white-space:nowrap">MGTA-145</FONT> plus plerixafor in patients with multiple myeloma will be presented as a poster at the 2021 American Society of Hematology (ASH) Annual Meeting on
December&nbsp;13, 2021 &#151; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; <FONT STYLE="white-space:nowrap">MGTA-117</FONT> targeted conditioning program clinical trial <FONT
STYLE="white-space:nowrap">start-up</FONT> activities are ongoing after clearance of Investigational New Drug (IND) Application; Phase 1/2 trial expected to open in December 2021 &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Ended Q3 2021 with approximately&nbsp;$192.6 million&nbsp;in cash, cash equivalents and marketable securities, and the company
maintains guidance that cash reserves are expected to fund the operating plan into Q3 2023 &#151; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cambridge, MA</B> &#150; November&nbsp;4, 2021
&#150; Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today reported financial results for the third
quarter ended September&nbsp;30, 2021, and recent program highlights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased with our recent execution across the portfolio as we look to
continue to allocate our capital efficiently to our value-creating opportunities,&#148; said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. &#147;In <FONT STYLE="white-space:nowrap">mid-September,</FONT> we
cleared the IND process for the <FONT STYLE="white-space:nowrap">MGTA-117</FONT> targeted conditioning program and are now conducting the clinical trial <FONT STYLE="white-space:nowrap">start-up</FONT> activities with the continued expectation of
opening the trial this year. The <FONT STYLE="white-space:nowrap">MGTA-145</FONT> stem cell mobilization program also continues to advance with a fully enrolled investigator-initiated trial in multiple myeloma patients, a Phase 2 clinical trial in
allogeneic transplant and the expected start of a Phase 2 clinical trial evaluating mobilization and collection of stem cells from patients with sickle cell disease.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Business Highlights: </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, Magenta welcomed Jeffrey Humphrey, M.D. to its Executive Team as Chief Medical Officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Program Highlights: </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">MGTA-145</FONT> Stem Cell Mobilization and Collection </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent and Planned Activity: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Autologous Stem Cell Transplant: Multiple Myeloma </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Investigator-Initiated Phase 2 Clinical Trial Design, Topline Data and Next Steps.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Trial Design</U>:&nbsp;&nbsp;&nbsp;&nbsp;Surbhi Sidana, M.D., Assistant Professor of Medicine in the Division
of Blood and Marrow Transplantation and Cellular Therapy at Stanford University School of Medicine led this investigator-initiated, Phase 2 open-label clinical trial. The trial evaluated the ability of
<FONT STYLE="white-space:nowrap">MGTA-145,</FONT> in combination with plerixafor, to mobilize stem cells for autologous stem cell transplantation in patients with multiple myeloma. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U><FONT STYLE="white-space:nowrap">Top-Line</FONT> Clinical Data in Poster Presentation at 2021 ASH Annual
Meeting</U>: Top line clinical data from the fully enrolled investigator-initiated clinical trial will be included in a poster presentation at the ASH Annual Meeting, held December <FONT STYLE="white-space:nowrap">11-14,</FONT> 2021. As disclosed
separately, the clinical data showed that eighty-eight percent (88%) of patients (22/25) treated with <FONT STYLE="white-space:nowrap">MGTA-145</FONT> plus plerixafor met the primary endpoint of sufficient stem cell mobilization and collection for
transplant. Also, as of the time of the data submission for the ASH meeting, all patients (18/18) transplanted with stem cells mobilized by <FONT STYLE="white-space:nowrap">MGTA-145</FONT> plus plerixafor successfully engrafted. <FONT
STYLE="white-space:nowrap">MGTA-145</FONT> plus plerixafor was well tolerated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Next Steps in Multiple Myeloma</U>: The results from this investigator-initiated trial represent a positive
step forward in the development of <FONT STYLE="white-space:nowrap">MGTA-145,</FONT> in combination with plerixafor, as a potential first line stem cell mobilization regimen. Based on the encouraging collection and engraftment data, the company
intends to explore further development of <FONT STYLE="white-space:nowrap">MGTA-145</FONT> in a Phase 2b clinical setting. This approach would enable a comprehensive evaluation of the multiple myeloma patient population and allow for adjustments of
dosing and administration which the company, in both cases, has identified as opportunities for optimization as a result of this investigator-initiated study and the company&#146;s other <FONT STYLE="white-space:nowrap">MGTA-145</FONT> development
efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Allogeneic Stem Cell Transplant: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) and
Myelodysplastic Syndromes (MDS</B>) </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 2 Clinical Trial and Next Steps.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Trial Design</U>.<B> </B>This Phase 2 clinical trial is designed to<B> </B>evaluate <FONT
STYLE="white-space:nowrap">MGTA-145</FONT> in combination with plerixafor, in the mobilization and collection of stem cells from allogeneic donors for transplant in patients with AML, ALL and MDS. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Next Steps</U>. Based on what Magenta has learned to date from the totality of the <FONT
STYLE="white-space:nowrap">MGTA-145</FONT> program-related clinical trial data and other relevant information, Magenta believes it has identified an opportunity to optimize certain elements of the dosing and administration of the <FONT
STYLE="white-space:nowrap">MGTA-145</FONT> mobilization regimen. Accordingly, Magenta intends to amend the Phase 2 allogeneic clinical trial to include a higher dose of <FONT STYLE="white-space:nowrap">MGTA-145</FONT> that matches the dose level
used in the Phase 2 multiple myeloma clinical trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Stem Cell Mobilization of Patients with Sickle Cell Disease in Collaboration with bluebird bio. </B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Magenta expects to open the Phase 2 clinical trial in December 2021. The trial is designed to evaluate the utility of <FONT
STYLE="white-space:nowrap">MGTA-145</FONT> in combination with plerixafor, for the mobilization and collection of stem cells in patients with sickle cell disease where mobilization and collection is difficult and there is a clear unmet medical need.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">MGTA-117</FONT> Targeted Conditioning </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent and Planned Activity: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 1/2 Clinical Trial <FONT STYLE="white-space:nowrap">Start-Up</FONT> Activities Ongoing.</B> The IND for
the company&#146;s <FONT STYLE="white-space:nowrap">MGTA-117</FONT> antibody-drug conjugate (ADC) targeted conditioning program is active with the U.S. Food and Drug Administration (FDA). The company expects to open the multi-center Phase 1/2
clinical trial in December 2021. The Phase 1/2 trial is designed to utilize dose escalating cohorts to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of <FONT STYLE="white-space:nowrap">MGTA-117</FONT> as a single dose with
possible anti-tumor therapeutic benefit in patients with relapsed/refractory AML and MDS. As previously disclosed, Magenta expects to work with the FDA on an ongoing basis to transition the clinical trial to the primary target population of
hematopoietic stem cell (HSC) transplant-eligible patients with AML and MDS after adequate data related to the safety, pharmacokinetics and pharmacodynamics of <FONT STYLE="white-space:nowrap">MGTA-117</FONT> have been collected in this initial
patient population. As the program progresses, Magenta also plans to explore <FONT STYLE="white-space:nowrap">MGTA-117</FONT> as a targeted conditioning agent prior to the delivery of gene-corrected cells associated with stem cell gene therapy.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Oral Presentation at the 2021 American Society of Hematology (ASH) Annual Meeting. </B>As disclosed by Magenta
in a separate press release, preclinical data showing that a single dose of a tool CD117 antibody drug conjugate <FONT STYLE="white-space:nowrap">(CD117-ADC)</FONT> supports efficient engraftment of gene-modified CD34+ stem cells in a rhesus gene
therapy model. The <FONT STYLE="white-space:nowrap">CD117-ADC</FONT> utilized in this study had minimal toxicities unlike busulfan conditioning. The data will be the subject of an oral presentation at the ASH Annual Meeting on December&nbsp;13,
2021. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Financial Results: </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Position: </B>Cash, cash equivalents and marketable securities as of September&nbsp;30, 2021, were $192.6&nbsp;million, compared to $148.8&nbsp;million
as of December&nbsp;31, 2020. Magenta anticipates that its cash, cash equivalents and marketable securities will be sufficient to fund operations and capital expenditures into the third quarter of 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses: </B>Research and development expenses were $10.8&nbsp;million in the third quarter of 2021, compared to
$11.8&nbsp;million in the third quarter of 2020. The decrease was driven primarily by the completion of the GMP manufacturing activities to support the IND application for <FONT STYLE="white-space:nowrap">MGTA-117</FONT> and future clinical trials
offset by an increase in personnel related costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Administrative Expenses:</B> General and administrative expenses were $7.5&nbsp;million
for the third quarter of 2021, compared to $6.6&nbsp;million for the third quarter of 2020. The increase was primarily due to an increase in personnel related costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Loss: </B>Net loss was $17.4&nbsp;million for the third quarter of 2021, compared to net loss of $17.7&nbsp;million for the third quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Magenta Therapeutics </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Magenta Therapeutics is a
clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell
biology and biotherapeutics development with clinical and regulatory expertise and broad networks in the stem cell transplant community to revolutionize immune reset for more patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Magenta is based in Cambridge, Massachusetts. For more information, please visit www.magentatx.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Follow Magenta on Twitter: @magentatx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release may contain
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Magenta&#146;s future expectations, plans and prospects,
including, without limitation, statements regarding expectations and plans for presenting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data, the initiation of clinical trials or the results of ongoing and planned clinical
trials, the development of product candidates and advancement of preclinical programs, projections regarding future revenues and financing performance, long-term growth, cash, cash equivalents and marketable securities, the anticipated timing of
clinical trials and regulatory filings, the potential benefits of product candidates, the timing, progress and success of collaborations, as well as other statements containing the words &#147;anticipate,&#148; &#147;believe,&#148;
&#147;continue,&#148; &#147;could,&#148; &#147;endeavor,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will&#148; or &#147;would&#148; and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The express or implied
forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and
timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results
of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities; discussions with governmental agencies such as the FDA; regulatory approvals to conduct trials or to market products; whether
Magenta&#146;s cash resources will be sufficient to fund Magenta&#146;s foreseeable and unforeseeable operating expenses and capital expenditure requirements; risks, uncertainties and assumptions regarding the impact of the continuing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Magenta&#146;s business, operations, strategy, goals and anticipated timelines, Magenta&#146;s ongoing and planned preclinical activities, Magenta&#146;s ability to initiate, enroll, conduct or
complete ongoing and planned clinical trials, Magenta&#146;s timelines for regulatory submissions and Magenta&#146;s financial position; and other risks concerning Magenta&#146;s programs and operations are described in additional detail in its
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on March&nbsp;3, 2021, as updated by Magenta&#146;s most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and its other filings made with the
Securities and Exchange Commission from time to time. Although Magenta&#146;s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result,
you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information, future developments or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contacts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jill
Bertotti, Real Chemistry (advisor to Magenta) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">714-225-6726</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jbertotti@realchemistry.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Magenta
Therapeutics, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 10,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 11,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 33,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 38,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59,637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (17,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (17,678</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (51,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (56,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (1.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,583,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,255,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,655,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,431,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEET DATA</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;192,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;148,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d231816dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g231816g1104044309572.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs
at the 2021 American Society of Hematology (ASH) Annual Meeting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Positive topline clinical data from <FONT
STYLE="white-space:nowrap">MGTA-145</FONT> investigator-initiated Phase 2 clinical trial in multiple myeloma &#151; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151;
Successful conditioning with monotherapy CD117 antibody drug conjugate in a primate model of transplant for gene therapy of sickle cell disease &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Successful conditioning with CD117 antibody drug conjugate in combination with lymphodepleting antibodies leading to effective
allogeneic hematopoietic stem cell transplant in a murine model of acute myeloid leukemia &#151; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, MA &#150; November&nbsp;4, 2021
-<B>&nbsp;<U>Magenta Therapeutics</U></B>&nbsp;(Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced positive <FONT
STYLE="white-space:nowrap">top-line</FONT> results from an investigator-initiated Phase 2 clinical trial of <FONT STYLE="white-space:nowrap">MGTA-145</FONT> stem cell mobilization in multiple myeloma. The data were accepted for a poster presentation
at the 2021 American Society of Hematology (ASH) Annual Meeting, to be held in Atlanta and virtually from December <FONT STYLE="white-space:nowrap">11-14,</FONT> 2021. Oral and poster presentations of preclinical data related to the company&#146;s
CD117 targeted conditioning program will also be made at the ASH Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We have made significant progress with our mobilization and
targeted conditioning programs and we look forward to the presentation of the data that have been generated to support both programs,&#148; said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Stem Cell Mobilization and Collection Program <FONT STYLE="white-space:nowrap">(MGTA-145)</FONT>
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Poster Presentation Highlighting Investigator-Initiated Phase 2 Clinical Data of <FONT STYLE="white-space:nowrap">MGTA-145</FONT> Stem Cell
Mobilization in Multiple Myeloma: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B> <FONT STYLE="white-space:nowrap">MGTA-145</FONT> + Plerixafor Provides
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">G-CSF-Free</FONT></FONT> Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study (Poster #3888)
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date and Time to View Poster Presentation: </B>Monday, December&nbsp;13, 2021, 6:00pm &#150; 8:00pm ET </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Trial Design </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Surbhi Sidana, M.D., Assistant Professor of
Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University School of Medicine led this investigator-initiated, Phase 2 open-label clinical trial. The trial evaluated the ability of <FONT
STYLE="white-space:nowrap">MGTA-145,</FONT> in combination with plerixafor, to mobilize stem cells for autologous stem cell transplantation in patients with multiple myeloma. This trial had broad inclusion criteria and included the
transplant-eligible population of patients with multiple myeloma who may have a variety of risk factors for mobilization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Topline Clinical Data
</U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Primary and Secondary Endpoints.</I> The trial has fully enrolled 25 patients with multiple myeloma. 88% of
patients (22/25) treated with <FONT STYLE="white-space:nowrap">MGTA-145</FONT> plus plerixafor met the primary endpoint of mobilization and collection of 2&nbsp;million CD34+&nbsp;stem cells per kg in up to two days of
<FONT STYLE="white-space:nowrap">same-day</FONT> mobilization and apheresis. 68% of patients (17/25) achieved the primary endpoint in a single day of dosing and collection. Three patients who did not meet the primary endpoint successfully collected
hematopoietic stem cells (HSCs) with subsequent <FONT STYLE="white-space:nowrap">G-CSF</FONT> plus plerixafor dosing and <FONT STYLE="white-space:nowrap">2-3</FONT> apheresis sessions. Secondary endpoints of 4&nbsp;million and 6&nbsp;million CD34+
stem cells per kg in up to two days were met in 68% (17/25) and 40% (10/25) patients, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Days of Stem Cell Collection. </I>The median number of 5.0&nbsp;million CD34+ stem cells per kg were collected
cumulatively over one or two days of dosing and stem cell collection. In contrast, current standard of care with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">G-CSF-based</FONT></FONT> regimens require a minimum of five days of
dosing prior to initiating stem cell collection over one to four days. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Safety Profile. </I>The regimen of <FONT STYLE="white-space:nowrap">MGTA-145</FONT> and plerixafor was well
tolerated. Treatment emergent pain was seen in 44% of patients (11/25). Acute, transient, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MGTA-145-related</FONT></FONT> grade 1 bone or musculoskeletal pain was observed in 38% of
patients (9/25) shortly after <FONT STYLE="white-space:nowrap">MGTA-145</FONT> infusion, resolving within seven minutes for all patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Engraftment.</I> All transplanted patients (18/18), evaluable as of the cutoff date, successfully engrafted.
Neutrophils recovered after a median of 12 days and platelets after a median of 17.5 days, which are comparable to historical data. Red blood cell transfusion was needed in 17% of patients (3/25). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>100 Day <FONT STYLE="white-space:nowrap">Follow-Up.</FONT> </I>All 14 transplanted patients as of the cut-off
date had completed <FONT STYLE="white-space:nowrap">day-100</FONT> follow up with durable engraftment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>CD34+CD90+ Cells.</I> The collected CD34+&nbsp;stem cells contain a high percentage of CD34+CD90+ cells, a
stem cell population associated with multi-lineage, long-term engraftment. 74% of grafts (17/23) were negative for minimal residual disease using next generation flow cytometry. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Next Steps in Multiple Myeloma </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the
company&#146;s third quarter earnings release, the results from this investigator-initiated trial represent a positive step forward in the development of <FONT STYLE="white-space:nowrap">MGTA-145,</FONT> in combination with plerixafor, as a
potential first line stem cell mobilization regimen.&nbsp;Based on the encouraging collection and engraftment data, the company intends to explore further development of <FONT STYLE="white-space:nowrap">MGTA-145</FONT> in a Phase 2b clinical
setting.&nbsp;This approach would enable a comprehensive evaluation of the multiple myeloma patient population and allow for adjustments of dosing and administration which the company, in both cases, has identified as opportunities for optimization
as a result of this investigator-initiated study and the company&#146;s other <FONT STYLE="white-space:nowrap">MGTA-145</FONT> development efforts.</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;While Dr.&nbsp;Sidana and her team are collecting and analyzing additional patient-level data, these
topline results are encouraging and support further development of <FONT STYLE="white-space:nowrap">MGTA-145.&#148;</FONT> commented Dr.&nbsp;Jeffrey Humphrey, M.D., the company&#146;s Chief Medical Officer. &#147;We believe this novel mobilization
regimen has the potential to replace <FONT STYLE="white-space:nowrap">G-CSF</FONT> regimens and to enable reliable, predictable, rapid and well-tolerated mobilization of stem cells for both transplant and gene therapies.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MGTA-145</FONT> is also being evaluated for its ability to mobilize stem cells for collection from donors for allogenic
transplantation in patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in a Phase 2 clinical trial. The company is planning to open an additional Phase 2 clinical trial for mobilization
and collection of stem cells for patients with sickle cell disease in December 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Antibody-Drug Conjugate (ADC) Targeted Conditioning Program
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Oral Presentation Showcasing Non-human Primate Data of Targeted ADC Conditioning for Gene Therapy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B> CD117 Antibody Drug Conjugate-Based Conditioning Allows for Efficient Engraftment of Gene-Modified CD34+ Cells in a Rhesus Gene Therapy Model
(Oral Abstract #560) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presenting Author</B>: Naoya Uchida, M.D., National Institutes of Health </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date: </B>Sunday, December&nbsp;12, 2021, 4:45 PM </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
preclinical study evaluated escalating doses of a tool <FONT STYLE="white-space:nowrap">CD117-ADC.</FONT> As monotherapy conditioning, a single dose of the <FONT STYLE="white-space:nowrap">CD117-ADC</FONT> allowed for efficient engraftment of
gene-modified autologous stem cells in a rhesus model of gene therapy, without chemotherapy or radiation conditioning. Engraftment of gene-modified stem cells achieved with monotherapy <FONT STYLE="white-space:nowrap">CD117-ADC</FONT> was robust and
durable, equivalent to that achieved with four doses of myeloablative busulfan conditioning. Sustained gene expression of hemoglobin F was confirmed at the protein level in this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CD117-ADC-conditioned</FONT></FONT> rhesus transplant model of gene therapy for sickle cell disease. Compared to chemotherapy or radiation-based conditioning regimens, conditioning
with monotherapy <FONT STYLE="white-space:nowrap">CD117-ADC</FONT> could be both sufficiently potent and well tolerated to improve the safety and risk benefit profile for gene therapies that require stem cell transplantation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Poster Presentation Highlighting Preclinical Data of Targeted ADC Conditioning Program: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B> CD117-Targeted ADC, in Combination with Lymphodepleting Antibodies, Enables Allogeneic Hematopoietic Stem Cell Transplantation in Mice without
Chemotherapy or Radiation (Poster #1682) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presenting Author</B>: Leanne Lanieri, M.S., Magenta Therapeutics, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date to View Poster Presentation: </B>Saturday, December&nbsp;11, 2021, 5:30pm &#150; 7:30pm ET </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This study evaluated the combination of a tool <FONT STYLE="white-space:nowrap">CD117-ADC</FONT> with lymphodepleting antibodies as the conditioning regimen
in a murine model of allogeneic HSC transplantation. The targeted conditioning regimen enabled complete donor chimerism in a fully mismatched allogeneic HSC transplant murine model, without use of chemotherapy or radiation. Antibody-based targeted
conditioning regimens could offer a more favorable risk-benefit profile over chemotherapy and radiation-based conditioning regimens. An improved risk benefit profile, in turn, could extend the curative potential of allogeneic HSC transplantation to
more patients with malignant and <FONT STYLE="white-space:nowrap">non-malignant</FONT> diseases who otherwise would not be eligible for HSC transplantation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Magenta Therapeutics</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Magenta Therapeutics
is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell
biology and biotherapeutics development with clinical and regulatory expertise and broad networks in the stem cell transplant community to revolutionize immune reset for more patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Magenta is based in Cambridge, Massachusetts. For more information, please visit www.magentatx.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Follow Magenta on Twitter: @magentatx. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal
securities laws, including express or implied statements regarding Magenta&#146;s future expectations, plans and prospects, including, without limitation, statements regarding expectations and plans for presenting
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data, the initiation of clinical trials or the results of ongoing and planned clinical trials, the development of product candidates and advancement of preclinical programs,
projections regarding future revenues and financing performance, long-term growth, cash, cash equivalents and marketable securities, the anticipated timing of clinical trials and regulatory filings, the potential benefits of product candidates, the
timing, progress and success of collaborations, as well as other statements containing the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;endeavor,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will&#148; or &#147;would&#148; and similar
expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of
risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be
predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by
governmental authorities; discussions with governmental agencies such as the FDA; regulatory approvals to conduct trials or to market products; whether Magenta&#146;s cash resources will be sufficient to fund Magenta&#146;s foreseeable and
unforeseeable operating expenses and capital expenditure requirements; risks, uncertainties and assumptions regarding the impact of the continuing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on Magenta&#146;s business, operations,
strategy, goals and anticipated timelines, Magenta&#146;s ongoing and planned preclinical activities, Magenta&#146;s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, Magenta&#146;s timelines for regulatory
submissions and Magenta&#146;s financial position; and other risks concerning Magenta&#146;s programs and operations are described in additional detail in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on March&nbsp;3,
2021, as updated by Magenta&#146;s most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and its other filings made with the Securities and Exchange Commission from time to time. Although Magenta&#146;s forward-looking statements reflect the good faith judgment of its management,
these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on
which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jill Bertotti, Real Chemistry (advisor to
Magenta) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">714-225-6726</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>jbertotti@realchemistry.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>mgta-20211104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/4/2021 2:50:04 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:mgta="http://www.magentatx.com/20211104"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.magentatx.com/20211104"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgta-20211104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgta-20211104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mgta-20211104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/4/2021 2:50:04 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mgta-20211104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/4/2021 2:50:04 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mgta-20211104.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g231816g1104044249813.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g231816g1104044249813.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 -\# 2(  A$! Q$!_\0
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M2OMWI)=.GN+BVEFND80D-\L.&)]CG@'TYI:"7L[?\.:-%%%(Q"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g231816g1104044309572.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g231816g1104044309572.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !] /$# 2(  A$! Q$!_\0
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M6OV)9?),GS<OC.T#&2<'/ JUI?C3PWK6GW-_8:Q:RVUJ-T[EMGE#U8-@@>]
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M-+\1P0>=#:9@N5QD*I8,I;_9)R#]145MJOP4ET1;Z?2[6&XV O9^5(90V.5
MS@_7.* )_ .MW&K? OQ!:W+L[Z?;SP(S')\LQ[E'X9(_"L7X-> M%\4Z1?:A
MKENUXD,_DP0-(RHAV@LV 1R<@?A7<Z<WAJY^#VMZCX8TW^S[6[LIVDB*D$2!
M"#G/7ZCBL_\ 9[_Y$S4?^O\ /_H"4 <CX=TV/P?^T,ND:<\@M"S1A6;)\MXM
M^TGO@X_(4WXNZ#IEG\3]'2"U"+J926\&XGS6:;:QZ\9''&*T+K_DZ&+_ *ZK
M_P"D]-^.4GV/XA>&[Z5'^SQPHQ8#KLFW,![XQ^= 'LGA[PEH?A5+A-$L5M%N
M&#2@.S;B.GWB?6O)M3B^"FE:O>QW[F[NI9W:4QM*Z1,220I3"@ GMFO09/%V
MG>+_  CX@/A>[>YG@M'4%8V4AV1BH&0.>*\J^#>K>"-,T>_&OO8PZD9<A[U
M08MHP%R/7.1UH$5_AQ<6&E?&O['X<OWN=%O$=58D_,FS> V0,E6&,XKZ/KYS
M\,:AIFJ_M"07NC6RV^G2%_(5(_+# 0D;PO& Q!/XU]&4P%HHHH **** "BBB
M@"M>VD5]936LPS',A1A[&O#)/#\UAXKM]'OE(5[A$#]I$+ ;A]17O=9NK:+9
M:S%&MU%\\3!XI5.'C8=P?Z5<)\IA6HJI9]4>(^(KN2^\17TDF0$E:*-/[B*<
M!0.W2LLC\#VQ7HOC'P'?3:C+J>E()Q,=TT((#!NY7U!ZXK!TOP#KNH72I<6K
M64&?GEF(R![#N:U4E8^^PN/PBPR]Y*RV/4_"=]-J/A;3[JX):9XL,Q_B()&?
MQQ5[4;B2&S<0#-Q)^[A'JYZ?@.I]A3[&SBT^PAL[=<10H$0>PIZP?OO.D^9P
M,+Z*.^*P>Y\74:E-N.S(]/LX]/T^WLXON0H$!]<=3^)YJ6YMH;RUEMKB,203
M(8Y$;HRD8(/X5+3)69(V9$+L!D("!N]N:1!GZ+X>TCPY;26VCV$-E#(^]TB&
M 6QC/Y 5$GA70X]?;7DTR!=5;.;H [SD;3^G%)#KN_3YKV6RFACBD\O!=26;
M?L.,'L:EO-:BLA?[HI'-E$DCA<?-NS@#\J=F7R2O8;K?AG1?$D<,>LZ=!>I"
M28Q*"=I/!Q5B[T?3K_2SIEY9PSV)0(8)%RNT=/RJ&;5)K>R\^>PE1S*L:1>8
MI+%B .<X')I\.K1O975Q+%) UJ6$T;XRI SU'!R",468N1F3IWPZ\(Z2TSV6
MA6L;S1M$['+DHPP0"Q.,CCBM+2M TSPW836^AZ=#:HQ,GE1_*'?&.?R I#KD
M1T2'4XX)'68HJQ9 8,S;<'/ (/6FG75%L7%I-]H6X%LUN2H8.>1SG&,$'-%F
M/DD>52>-OBCH[-;ZOX,34'1R4F2!F'M@ID'Z\54TOPKXP^(?CFS\0>++ Z=I
M]FRLL+KL)53N"*IYY/5C7M2W[":UAFMWAEN-^$+ [=HSR156XUWR=/-['9RS
M1K,T3!64$$/LSR>YI6$HM[&K+$DT312HLD;@JR.,A@>Q![5R1^%G@<W/GGPY
M:;RV[ W;<_[N<?ABNB74 +N*VFB:*62!ICD@A " 02/K5>#6UEM)KU[2>*R2
M(S),^/G4=PH.1D<C-%@Y67)-.LY=-?3GMHOL3QF)H N$V$8VX';%5]%\/Z3X
M=M9+71["&S@D?>R1# +8QG\@*FT^\EO(R\MG+;# 9=[*VX$9R,$U<H$TT[&,
MWA306U\:\VEVYU4'(NL'?G&W^7%2ZYX=T?Q):+:ZQI\-Y"C;E$@Y4^H(Y'X5
MJ44",G0O#.C>&;:2WT;3XK..1@T@CSER.A)/)K+O?AMX.U#47O[KP_:27+MO
M=L%0Q]2H.#^5=510!C1^$M AUM-9BTFVCU&-0B7")AE4+M '8#;Q6S110 M%
M%% !1110 4444 )1110 4444 %%%% !1110!SLNF7,GAN[LC$?-EN7<*&QE3
M+NZ_2J]]H4R6^N16D$C)=01+$&E+%V&[(RQR.HKJJ*=S159(YV2PENM(6VAM
M+NUQ=1N1)-N< ,"6#;CVJ'^R+X:+-I@W>9+=_O+IVW%X\YWG/4X 7']*ZBBC
MF#VK1RS:1J(TNZL&8R$WJ3QS( A*EU9B!T&#NJQJ>C"/38XK:&>Z8WB3S?O<
M22>IW9'.,>G2NAHHYF/VLKF#)'<Q1Z;=V^GW!%LSA[9I TFUAC.22#SCOTIA
MTZ[;PP]L8@+F2?SC&&'RYFWXSTX%=#11<7M&95W92W&LI+MQ ;.6%GST+%<<
M?0&HM.>_BTX6=QIA+V\'E[O,79,0, #O@CU%;5%%Q<^EC$T"VN+9KH&WEM;(
ME?L]O,X8QG'S8P3A>F!GUK;HHI,4I<SN%%%%!(4444 %%%% "T444 %%%% !
M1110 E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "T444 %%%% !1110 E%&*,4 %%&*,4 %%&*,4 %%&*,4 %
M%&*,4 %%&*,4 %%&*,4 %%&*,4 %%&*,4 %%&*,4 %%&*,4 %%&*,4 %%&*,
,4 +1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d231816d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgta-20211104.xsd" xlink:type="simple"/>
    <context id="duration_2021-11-04_to_2021-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001690585</identifier>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-11-04_to_2021-11-04">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-11-04_to_2021-11-04"
      id="Hidden_dei_EntityCentralIndexKey">0001690585</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-11-04_to_2021-11-04">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-11-04_to_2021-11-04">2021-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-11-04_to_2021-11-04">MAGENTA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-11-04_to_2021-11-04">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-11-04_to_2021-11-04">001-38541</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-11-04_to_2021-11-04">81-0724163</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-11-04_to_2021-11-04">100 Technology Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-11-04_to_2021-11-04">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-11-04_to_2021-11-04">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-11-04_to_2021-11-04">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-11-04_to_2021-11-04">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-11-04_to_2021-11-04">242-0170</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-11-04_to_2021-11-04">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-11-04_to_2021-11-04">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-11-04_to_2021-11-04">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-11-04_to_2021-11-04">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-11-04_to_2021-11-04">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-11-04_to_2021-11-04">MGTA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-11-04_to_2021-11-04">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-11-04_to_2021-11-04">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2021-11-04_to_2021-11-04">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140096586401608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001690585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MAGENTA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-0724163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Technology Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">242-0170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGTA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M4$L! A0#%     @ 3TED4T""D2'M    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 3TED4YE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !/2613Q>EH0E<$  #8$   &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 3TED4Y^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !/
M2613EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " !/2613'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 3TED4R0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 3TED4V60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d231816d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d231816d8k.htm">d231816d8k.htm</File>
    <File>d231816dex991.htm</File>
    <File>d231816dex992.htm</File>
    <File>mgta-20211104.xsd</File>
    <File>mgta-20211104_lab.xml</File>
    <File>mgta-20211104_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d231816d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d231816d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgta-20211104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgta-20211104_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgta-20211104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mgta",
   "nsuri": "http://www.magentatx.com/20211104",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d231816d8k.htm",
      "contextRef": "duration_2021-11-04_to_2021-11-04",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d231816d8k.htm",
      "contextRef": "duration_2021-11-04_to_2021-11-04",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.magentatx.com//20211104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-21-319497-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-319497-xbrl.zip
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MO-LQJ_2XP^R(430?@*WW/<FTB,S:^K,-7=QCI"(=ADR49,MDYY@WCR?78![
M)2$RZ/X#BX8D9\3AM,N=<"F].%5$AD =PWY$M#.>W-CT]@H\@'<U>4$1D@&=
MH.BPT=*#&E&8D-R&AG+>QSG&! S("/9C(\W_>*R)*<0C<#JL'=VYM6:!D($%
M[E@$1WZ>&Q.<=O;8\MRKO0(IR1OF=VNO;G5(W,#W)<@798Y0&.IQ$#XQ+X$/
M00<*ETW!5*%(Z%<5AD96Z4$XG-2T P[T:WL69TH?Z?O(0%N&ER*RD<*HM3].
M;%C-=0/,:S"FM-3LWPBA)DPS0,6]&:!86Z._H0]')C05T)D!I$F%]:H:GE@U
M5+YGU3!U6/5-&&3CT).-^/<0^B)K1Y7X&(;J+K[6X[)4X<I$>XZ@":A.:H $
M3YVOT&F8>@P3]_-8XP_])*T,5LG?D]?0]R.?&Q31,:Z."NG1%SMDFOAIDY)W
M:57)NU*>*7E/%WS2@M"BQ*86K)%/MJTG;'?7AI+P_9YVL62>F:<V&U4J9GZ@
MAOIP#-BK5F2O;&T(4@TNR3(*3.KV)];M"+F3/NJNZ>GJJZ:G![T]NCGYBL]/
MON+6Y -79LZ% 6<)1\A70H:U%'QGZA/2L0YT$>0.=DB:F"VDEKYO]PX=57V[
M/HMDLS%F11=1A^S8%=.L!-\73>SH7618>9GJLHE5!:6VM :_8!I($FMG2Y/)
M>[X"G9(R+9+(.N%.IBE?K:%_WKSO02^AMYL?;FJ=SZU&^\D35<E7'89UIV\!
M%Y$ON6FV)Z5@90?.F%@TP"*3CIS"=_WA,N!V2=@M-'CA:\BZ#-RQ'@8^.)'.
MRD0=,"0*7!BCIP/B##P!&]NK7W81%3@.YYR5%WVSD$.7NF=S(9$1>U?;.&PK
MSRB>55Z&PY:P6J6U85WJF_JB!+E^7=_*^^.;F-D=W\UQ.$,;OHJS^E3O*=C#
M = U%<DMU5FJ[_7L)]'2Z/#'^.>A0D$62%LQ?\!<<DWQ+OGX1=! G]1[7C+4
M!YSU$J5%3"]$=4<( &[UNQY$FC<Y*;Q_CSYE:85/>5$(_^,1_=^27/T?4$L#
M!!0    ( $])9%,"2K5:[AH  !S#   1    9#(S,3@Q-F1E>#DY,2YH=&WM
M/6M3X[BRWZGB/ZC8W5-0U\GD!83'4"=#F(&]O)9D=N^YWQQ;230XEM>R@>RO
M/]UZV(Z30,($"#/9VF+ D:56O[O5K1R>MB_.CPY/3QK-H_6UP_99^_SDZ.3_
M"GM[Q?+A!_4G//^@!Y##3U?-_Y!/7XZOSJ]N/F[\=7K6/MDX(NMK,.B8^A$-
MCPZ;9W^25OL_YR<?-^Z9&_7WZ\5MYF\0VV,]_^.&1[O1AISKV@P;V&&/^86(
M!_NE(#H@^N\.CR(^4(^ZW(\*@OU#]\OIWUU[P+SA?IL-J""7])[<\($-*S7.
MS[Y<?MP(6:\/2QU^.CIYZ+,.BPANBQQ^^'1T^.'Z* - 9O8*S)Z#9PR<C:-_
M^1T1'. LL/%I^YCP'B(*WCB[^$):-\<?-WJ5:KE>WNF5RZ5:J5:KU/;JY6KQ
M6]##3;0_;IQ??;E2R!H%.+.2A'A1*',D#27.+NP>_&&3=I^&=D#CB#F"W-"
MAY& ARQTR1^Q'<)P\IGYMN\PVX//1>S!YP;'CV#G!4"V?9=<A[P7V@-R"L3W
MD &>!.9E$'AV]*]?RMOE W+-!8O8'26PEL=\2ASXR1Q EFL#>KLA'X!H>"2P
M(P8O"\)\8OOP\XZ*B/7LB(<%>"%B=D1A>WU;4%)))XE"Q#N]L[T8)O![1$1T
M0!SJ>>MK ]YA'OL'GG.<TX7!MB\"S_8C0GU 4S<:P)(D%OCBX>>KRW8BN7T6
MT8((;(?N^_P>.&#CZ.)+NU$HU[8//^#((Q)XL8 ?-&0/=I>'"'BRB7L6]<D
M>('! #(84@_0!$]AHQU*@I *1)1+;$%L$G"!;&1').K#YDJ5,FD,8%H'\-#B
M#J/1D/ N.:4#P(;'>T.RV6B=;I&&[\>P^0M*Y<ZYO[[6I X==&BH!+1<M=1T
MFA:''\[RHO]ZC# C?LN[!K\10$(120[W789$Q%T&FL%S'*!F7U][9'X!$T:%
M.##SVP[P)<P+\-LA!?3U."X 7 '$<#QJ [<X%#%_EC C  &+X7:;8=PCFV>7
M3:!# )SMR \/-(>6/U0,:SX$U,%=1)SP@")G$T.EB<1Y&S$]\5V \8^J DFR
MKQT KA\8,!WUAHJA?BWO58H[!.;V8+/J&>S'L47?DC\)_3MF((Q2"%#D .!;
M&MD=D )!G3B4^+:4- *S.WP0V/X09-5FH&V9+T@O9JY$?-0'B9"3HKB$=YI.
M681V8ST/8#94\H_B#3B&#]5FJJ_(_*B$C^U!)V1NCUKDHH&J5ZY?.B"7_"XC
MFC4EF>MK^M-)YL8"QG.*9//2%J[]]SY! =D"W"6\7P"6[E'283RB3M]7ND&C
ME+CT#K1.@#CQ86F/#*C+'-#  CX2X(LH% *P,$+2(D84@J8.^#WP)O!]HDLS
MFE/@2P,.A##*SH(GKCT$*J%QA%F[B3T,M3U$]8A+1&@WU]?^UH:32J9KT2#*
M8*9:4JA13!)2Y-5$ZON)62N^M$^ DE';/?B+2JX#-0YR[2K)X'%H *,/P-7*
MP#@A%T)N$_'0Y2 BJ-_O*?$XOP4DK:^!)@,FC=$8HM'CH#2HG,VQ Q:AMNAV
M@48PL3>4"@,^0M-&"TY(%7_S &>/?25("&/]@ B;N>1W6P 87^S0]6EHD6;Q
MNL^\H@4N 9#;16 1H<=]1KOD1($-Q+["%7'\) XL$H6$,_]I]3U@;B$AI664
M[#V%7:,NI4I006$B,1TJ4JY8L&7 72+)X&TY(':BA,4G&8WGF0S)"$J%*9JZ
M6C,I=X-WU]=0W9N5U8+ _X(, 1M%1//\+D<JD".^3;)S3_ $'BFHMGLG=:E2
MZ* O/6 LZH?<\P#@*4Z6@A7T^I@#DXJ\/<T58^"%(&L#,U'F9%TNH_,3!2ZQ
MBWIFZF09OV[,F7-P#XY&=HH9H5S*44],,.<6MB$QYS*!HES4HJ--[@<(V\ \
MZ" .(@[Y_V$ $P\].JI=Z&!,N>"C  2HT $YO2UT*/ VW;>]>WLH,( Y/+TA
MK;/_!S)7-\R4,HC<_V5/_K=!_CIKMD\_;I1+I=\2.WU\<MD^N5FZ"!/MW.'7
MHT_H.*,@I\'&/N#SZ]$3$<?.(D  E73E1-QX4:G^NJ<>F$!@K]]!F89T2$[C
M0="'7V!(L5E$J6# %ZD&;%,4':$UXP5:26 ]K1>+Y#&?K+XX9(X';J.XG$S-
MA: 2 7C:?<[KHA9*W#%*U$5>-(]3T7P=\&^4,98!,.@:=&T:2E4/]Y^*?Z?!
MH!^A-.W7?IL?ID8L@S4.06**JG:B#L&=,]KU0FO71S,S.W,F9E![M1N?SD_,
M5)^N;IHG-P70.N>-Z];)OOGET9WDM[U!U#0?-TH;Y/CD_/RZT6R>77Y)_FY=
M-X[-WUF-IN"Y4;J/?"0;&6T)7C_X)_OV'6>N'MA,7_XMW56[F?NT JKR3ZTK
M 2N)WE0J$#7\WJ37RKG7)BR0G6AT+%)GY%.-7S)*'3*=L6=$-3+16=9"GXVE
M08Z-N6Q+<]F4?KU%VCK5TL0,"PK%)7V(D L#490A"3*(W"W\N,$?R"@C K)B
MO-ICC%=]'N/E^759&>_K49:AT SM*TC'?[;BL--GI(5!NZU,K$4:0C#P[D E
M@UGK@HO 93QYH2-0]"W1$VR"AA8,\U;PX2>(DES)K1=V&(+OGNK*C&4!)1I[
M=JBCE"$FS5JP$+A;+OGJ@SD/!2A]TG+ZG'LC:WHR F%BBM=K)4*%;GO!LSL0
M,H^ZH\II'_%,=51CHP&463H@XJQ.?1(C80:%#SH0-<M]2H\US2M:*N"6)I:.
M^+F 5#LU,I."=37ADXG)XDHAK!3"$PKA2;8&HU,X!T$S7)W8)FF%@ >O59K[
M6B6_M4Q'.M_=.M7I[/4UG<^66@=-&9EV;("2-UM$FPLK31Z>^8X7N_*U- T?
MY.##55+P3+;=(GWJN6DF]TGTE,L@\XG(XZ:+H"8Q&G4\+JB[OB9H8(<RV6J-
M)BODCD6?WTMM R!1C ^&!?D/"6@HG=_->OVW+=1XB:QO5BH?*MM;L&DJL2!E
M_[N/.094X20(&; 5XMX-./-E("]BD[^:EJK(1>XPX?I:JJ\ )9[@%D9C,)O,
MFP!KFM\5'N+.@ FA7TZH,S!D&3E+VBS7/Y3K6QF-:-"0T:-&M[JD,_Q^](C8
MP>26X4MYRD3=XBP'%$]-?2^SB:C@N8?I;CGM1,6]BB!6>EOK[=3U1RV7CSFU
MD@4A2E+U2K-.]9.T"@VIUI-*<<HC7E!AL Z*Y;T=NL;)T^<0\J05!'GQ[I$^
M0XU@ 82LRT(1*9LQ10>%M >(\XODDTSI<P4G]1T>AW8/DXT9#84**WM8C$K(
M&CV[ N4'2E#F6^E#X.'92#<.84CX[,UG]IXD1SNI11 T0FV'#BD02A[4V4Z?
MW//80VCE<9LM 0QIGX)PW-$DEZKRI;B!:>E=0&8 3G:R?4SGWBMWT_T6"XD'
M(7U=E\NC<SG('0!P(@HUE?K,Z6?19.%>@)'[>*2'1X"P*2*/)5B7J9/PD:,-
MN1X/0/\GI@/IK-A4[6 ZCXHH=H?Y0T84YIT#6$929FY29$BYOD:[72P$6>G?
MI_7O]@NHW_>3P&FD1R&3LX -)XZT.F8N.:?Q+1TPFVPV+LZW+/WI^7 0]+DS
MC&"6S(CS\RWD<?"8\6UWB%,*'-,:^BZH<0!N\Z+9PHS/UO0([T<\^?@Q).<G
MSWU.27*N\IDK-_C[\YG%0\DVGXZD!S7M+'ND5,:\85)_SPGIGO)EM<\\YV%W
MYKS=Y3X/=6E%>O0^E@$$ZP+&Y?Q<Y5N;K54&<"5"LT>24H#2Z.D><U+F^!W=
M>JSWT>5E+@I*DJV+>&3K1'FF\F>^I(@Z)R^$U)N4VG/-D9?R\F$4B*N4 !")
M@12HM%2@0SU&L:Z016/AB)\)1U0MEHI%L(HDQ$I% E.;2$@%NE.#H>?O=G+<
MVG <'KJP&*8*S68R4:@-HU3H8Q1;1D/D$(;E$"H-"M$5EM=AU,H%?5:X*K.3
M@&6G3X7!"9Z\0.2TOA8+FB0%#%QC(6C^Q&457ZWBJ\><Q"E5*,"\UR,&KZ4J
MP.3(IJH 0U[$2A6[P\.,.>YX,>U@>T>'\:(T^!@D/<&%<]:3[,U;3V*$7-7.
MB:28/"M+8X5XHW7FV=/+4<<F.<R4T\61.<M\"0?'Y.QG]W#&?)<)Q7Q@@FCX
M^*2X98:G$Y@^TIDA> 739ZK8G\0^'FT,=/V73ZE;5)2?4F2\L.*O><M?VZ;\
M]3A;_OH:17>SEEJM]/-*/V>#>&R'R87Q3W)]2]9>?TUJKQMI[?65:M51L7];
M5Y6KH\3Q=._<X@7N(NMP=UAPL<7'X?ZWN(?*<;/1/-YZHO8<U8DCJTJ3^O"O
M18BN/IO:%MDVU!AU#S<_-QM;2CV;YHU)>E[Z2@75NI.V&6%Y_0QZ/]^6E+,
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M]C^Y  CT<I^*6,BATLN1Q:_P#O5F;"5+ #-P:9.?:EMU:-ZW78+>R4!:I >
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M3Y\%R/N9JXI@EW)_.!WN.(N6K.J7,"6Z3%V0T<.0&!,8*/EA!!"H:4(.KAR
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MN>US#[_V5'V=B+3$T7 Y.*]<W[-VZN]+\56MO=*<LI(/M=<G?I<'N)A7S?_
MP]/VQ?G1?P%02P,$%     @ 3TED4TKU[M3-%P  *5\  !$   !D,C,Q.#$V
M9&5X.3DR+FAT;>U<;5/;2+;^3A7_H8NIV4IJ; <32 @0:AU,$N9"PF(R<^=^
M:TMMNX.DUN@%XOGU^YS3+5D2,B\9R-Y[BZTM)I*E[M.GS\MS7EI['\]/CO?W
M/AX.AONK*WOG1^?'A_N'_]U]\Z:WL??"7N+^"_> V'OW>?B'>/?AX//QY[.W
M:[]_/#H_7-L7JRMXZ$!%F4KV]X9'OXG1^1_'AV_7KK2?S7:V>ULZ6A,RT-/H
M[5J@)MD:CW5:/!;*9*JC;F;BG?4XVQ7N>FRRS(3VUL1$63?5?ZF=_N)Z(D,=
MS'?.=:A2\4E=B3,32LPT.#[Z\.GM6J*G,TRU]V[_\-M,CW4F:%EB[\6[_;T7
MI_L5 BJC;V#T!CW7R%G;_T<T3N-=&@4+7[:.EO>(47CCZ.2#&)T=O%V;;KSL
M;_=?3?O]]<WUS<V7ZV^V7F_TOL936L3YV[7CSQ\^6V;5":[,Q!0_%,L\WD/F
MV8F<XD**\YE*9*SR3'NI&$21R2,/[PXE?CM-5$H/9=I$J3A3@<R4+S(C=):*
M$S/6@?Z+?Q0R\L6!B7Q-5SJ:XE4S3628KJ[(3&0S)3;6-_IB$*I$>S(2(^-I
ME<V%F8B/*I29"<QT+IX-1A^?$Q&Y#,2)4AF-U+*?C\Z>H_U__-3?ZN^*4Y-B
M29<*BXX#'2GAX2]6$ B?&#1)3"CVWG_^= X=*91BIC/536/IJ9W(7(&Y:_LG
M'\X'W?[FUMX+>G9?Z.A2I9F>8N%)%P-FFCE[.I,I.+68)$LT_NI(A'F0Z3A0
M(IRK #0+1]_>BZ/_&'.PXMR#K*23/!!>=?.O=#83H8E,QL(U%P?#?O\UA"33
M8^//A9_D4WKC:PX.*%J?%'&B0[H(C:\"DHLLD5$:!W@)Y"4"TJI$,1Y^3K5W
M 7YX*L!>Z%01YQI,6:*[CRPR-S+E5D9X)ASKR"H5OQ',PW@&GF#S61W<NQK4
M!$KZ= L*J283Y9&@0M\"Z!*8I3TQ8]6*#50-5VFF0LNO"FN9]V&>D&R7K)=>
MGCE1TSZFR2]4J'^DS.T?R'"<:'^J.N)DP!.O[XI/YE*%8Y58Z[S989NRNM*%
M-7,&^TNK6=M[\66?K(A]Z-DGF?KRSQU!2OF\@^47ZM9-,[PMQMIDRIM%UB9A
M0V(98:O4)=@1$[\CT!&(4/G: ]M2_)3"]5G+"*II1V#PO#R1;#IB<Z42%MF6
M#4CII= D> Q/@_2T@SN^G&.CK2WV,8 S0G>P--B"+AFJPM+ @L-TI-92P?#>
MS_* :#OG/6S;8I5AU4.T&+$>[9(UI."0@MAY*B9J2-\E+1NJ!<.P<$)_VYMT
M>(\4-"/PB:1!1IL@V7]=ZB3#H\'<,FNH/):VVSG0[V/]G6+]1%I/?$XP*8W:
MLHJ4",6-NB])%NZ5Q<?*'41_\]4NW*BU'!GT2M%3-=,26V<+@P&NRR#E)8;2
M!TLMN\")!B-ZCPTYR!QNOM[]';R6EXX:4A,]H2W++,VPD];*F3RIBPM8M[IR
MXVI39N^5$H$Q%R0R5S(IN5=E-SN30M"R&5C"%(V5BMBK) 7;TSR.39()+'E6
MSM*A=6SOBE3"%/XJ4XSW 1/AM8X8]DYG.NAU&"AI'Q-:(#33:B(.ORF845+;
MSQ.LF9YO,TYV(PB$ UC#3#F8#4S(_]^+H5#S0-4W2(77]H=NQ1B_.TZ4O.B.
M%3BB=F1P)><I0<R]CV=B=/0_V.F7:\60#/-W?GK#_UL3OQ\-SS^^7>NOK_]<
M^K>#PT_GAV?_ZV( 0K"P]B.R-0=D:UK0:!"02\2EPZ*W*_*SPI8]=\I,VV)]
MQW)M>?5 RSFUAJ**N<5'A#@!A3DD]T=5TWUTS70?%-:$H?OW6.Z2FZLK)PW3
M?5*8[A-KNG=N@>4/Q91SG05JA^:Z_W)^$:<!',0W2>X$,G )#84AO76<6Q_X
MT#T8O>^^3U3A98L9SV0,(T'2AUA)RS'X];$&P9;(*Q$XR-EMF3RM/'5> VJG
M#B%8DWE]2P:E+(RR'.CRF1.IGUYN;V\_)UE^[.T:$HJE]=./9%)_T_B]1;*M
M_)S K,MYIW2U%J#U7UIDUQ&O=M;7X[" ?]OVZO!<W 3NMQ]D*5_VSQD #1G:
M"6L%'I5[HSP9S[08:5]&$JZB-X1?&:2I!BC%]D-^)_"6AH DU--A3Y(*<FU#
M?:E3Y^K>P1]:(3R126*N*D)4L8Z0KCR0B7-%<P(*(TP$2?3%EPA>*P'FG(N1
M-S.&<6 Y94#.<J;3)5"R4PJAB574#>086+D.*RWNLPA37<H@MPX8]R0IA05R
M]XBJ.XNP^GK\%)<VH&.A-NN=6L#4U,+-A?JUP?32$,8U'6Q#M.",7=I,^@@'
MC"2@Z04Y[X^78!GXE3>!;_MVZ0 [Y61=&(^I)NL1FQB[5("8F^<65S,L#X$#
MHQLI+F52@.)$IT!(TL-&V=56H=:-2/#!M,FE3VI.JO"N2W)UK^Z9JB.T=#YX
M=WQ8#/7N\]GP\*P+E',\.!T=[A3_N)'<YMK6A!WF[=KZFC@X/#X^'0R'1Y\^
ME->CT\%!<5U%4):>,XNUQ%NQ5D%G.B*XN",O$5^[!X?ERS\O%G4^;/RX 63V
MFX-F8$H)TRSB(JCZINVU?N.UE@FJ ]6?I<VI_>K8*^J;(Y8+RATY34F44TH#
M)7/6CY$BW$]7AY$/%PK1[U'RH6(^8&K$)*>8344)(3Y?;&S=JJ3;VS^S&2V?
M>[:Q\6)CZSD&56R+^+U[ XX82EZQ-R)4F0M&[)J46P6I9#/8@>$J\2I^WK ;
M!+8%=.=@^'+S%WNK8K=B.-6+*5FE/.; Y\H@R)FGO+9;J4]EJ+IXO*#^&D4R
MAF^ _T.(\HH9MN#KL_YKYI?T$.I<.N-];9F<6TH!70,*OM@2^2:U2:SJ@LEJ
M DQ5M@V6S >2BDP&)B[C8EHFVH)Y,9I"U+@DZP6J/XX.TN=V<]-\G*H_<PK9
M[H;WEFUR946W#K31?5D,4S)7I%@#)05Z%7DOULB9@LVZ+-!,KUK$8W7E+J+!
MB1823/Q$NUKN)$;=7*?K=;Y>9*- 96QSB\'<^@HV&_AS1G_(X#[9[R?[[>SW
MT-J?2@QS4-%SLMYDO"EW*B,1Y9Q@P^-;O?46D1;7)9KEMZ+L7AXR0B+I%.:2
M1@/,@%Y6C&%51Q?@KFI_C@@X1D!@:=:AQ&U"=H& MT\Y)8S@24Q[-Z]PQ_!Q
M#)#L-^+'1$W!XBC%/_[,-65$10B\%.8AT3"A7%)IW]V:8!5IL48X $[WVM:X
MX V>G5"ZC49:IL__3]-13P;F_[Z!&<D)1344#^M +4R*TYWO2GQQGG[ATJ\D
M^4E*@R$FM.EA0!2"AB'9!16JA/*XD&\X47HXI50R_KVYV81)?7*F/3&@@EK'
MQI/T4^<!S$BQB*XK'#1LR32AC'M?C)T]#//4RP.37JA 94#.)?$&0"@A#(?K
ME]> \1M& ^G,)!D,K)QD=RF(7"]W3SC\93!A@LNB'(H94\#'B*P<&.0B\2 H
M.?B$-Y[,P<WFX#""H$]8,6UL.*CE;:AZNM#&[1?][><=EW.B_(I,B^(0%-1,
M)E0C@I[6(@ME9X -6%WYI/(L,?%,!^2C/?*IF,%JA2Q0#4;L;UA';0T+QH3.
MI6W/O>YM\9,=Q#S:FPF9N,I?PO3!5\]TFIFD+!/VQ!EF''..;Y&CLNK%ZAPI
MY5ME[K]N6*.7UA@M=?E/.O6D4Z138)T CK_=SK\'O#17W2]QK[#TI(*D@?W-
M)4I8T[@N5 Y(EHH&E"PEP0^XWGOKS-"9+L@LIITP(13K,D;W<ZL^JF(<GCS)
MD]3?*/4<<1X,WZS_PG%K)=58AIM+\G 4.DI.=LWT=$:1*G6%42L11+TR+#_=
M$;*2J:EF^&6:&D\O\H^<M^1F'DE]4(&)IETXD+ NUJ\MYN0[+C'W\KD-DR,U
MM1U(G(RD0!).A#L5J!&D:)K+.8Z,U+>LZ(;@DB3IDS<'-U66+,W[/'81[A-1
M-<I4G+85H7]$66[ [5U>HL?6J7*IIMZ;0]6PQ!=_YC(A_ZYD0FTJ!! "8G"'
MK5VM#^N&\IG+:R?*=;#8/BC;_@6IB<M&%U?Y<VUI')C<)_2Y<\T,!AL"&YL,
M,Q!E$YVDF>!BSI).+Q>)]:R>O*,\AS"66A5Y!K9Y2A)7R4T03*H(-0.=3K4+
M"E1B?I^;Y=2W.*!^N4F>4#OH=W.@P@!9U"S'9:42.JHR;I2RR^"ZGHSCQ$C
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M7U._F/,<_B5YEL53B^"R_'P')1+-5UO$J'++[45"_<>Y&V\"1!UY?*Q")6P
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M[?89Z_N8;3=RMS-L^':K'3CT^C]02P,$%     @ 3TED4_@O_:^.!@  .4<
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MHWDLJW9+ >6YB'BTG>IBT@TN]25Y\QO;5H6S(+DC2,NM8$E0$VA+!(G@32I
M6@+B&J"+-,:XQ=;S.-?OGP+L,_369H9FVD-5GG=S.L+8VCCN'VL"[;X.$:N9
M,!CEQH#2MYGGLF*OE##>,,G1/Q?^F7ZS4Y?*)\D=XVFW@B5!%,!:!*G)34J
MK@&F"!G$+;1NI;ER_W3+A\]LP<T26D2?W+ RU_;<3A</!4:P.*;YTL&F1[MR
M>*P I@31NJ&-OBW+ALK-T^%\*3R4*Y3Q397;2 _1%-=Z\;*=HE^3[@-2G<)>
MS2963FD^"A7D:2=CIR#$%2$M":8FT:C\#[XLD_-\<W2C=,$#]FD=SIFL-S?Y
MO$Z'Q&( [<>;X_]4BY9UHPZ)/!'6U/U:&*[4-!VN,W=SZ>M%%+_CR2WUY[!;
M*-(IR(>L887@YHB7"M/RKDO!;BU:^ENU8AF%9_BA&XQ3W]<V5/K/%1=L5&\H
MK *=#D29)3P0V'P0"D5IAR#5?Y-M@*D$UX)J9=.:#<L /,,+^0!,]>:UG.&#
M>!;^^?27 +_%C@W]QS R\)]*MH2]*0,HP12B19[:0!GPU5R0PQZ_9;B6-Q+O
MN?!JOO,MTG@)V!<9L['_))9L *RZ+4U!\MY/ Y15HQV%5JR4S4,-/^1#<8,J
M<H._^*K^S2"[PDL8"+LIVSCL1)(-@T6UI5%(*H$N17F#IST;96-0V0O)8U7&
MIF1N'>QW<[IZJ,K6..X?:_1(U9X.$;[Q3WZC3$,K?9\[CU-5;)8"1_/,8W"S
M1%'S]N)^7D=8%AI ^_$F>-JUB!"-Q2%6I[K!TDZ_>53K-$V!ZQ^21Q$34PS#
MM4AOWZBJS!8D=P1NN14L"6J"<(D@$<=I!=@MT9CE%AO/ UVW>PJH;S'@'H^X
M6'S4ZW')W: JT;;,CG N,8%%$4U +E(CHOA1'C+]Q@BWU7*>WUI]4\![(YF9
M%:;AB!\Q,U]'D-=W=]67$F4*'<%<P10>BFP"]R%5(LAU&<C7@:00Q)4:X]ZV
MB3SVSW32P@!<*K5FLOD86'1>QC 4&[2/Q%X\X6 4:+<U'DFY5J>D)4>ELU++
M%LF"AWEKO<[:CL;S&8^"RO=!]O.Z6NP4&4#[\48+':L6U3(G%0>M#K%\\U5.
M*_WNK'%J-$V!ZTRZYMN^M]MPCI67YD^2.@+5WCI:#C9!U")$Q&>J#(ET8S9;
M:#0/9M5N*:^AYQMOJ3VS.D^,VW,[OI9:C6!Q#,4U=5^/^KJ:5:!Y8KR]OJW7
MUXK-TWTV>!XRN= 3]*O$AVBI%RDK5]3\%F6!1*>?#I;;PH.AS3\?+)$E(C[]
M4"TK!$DE2$L1?3[8H@W+!X2UO1 .PD;_+!&*F[N/R1>1:DZ!);_;$2@VA.5Q
M!/ 7:!*3OX'',NFWQZBP;\F C?DJ+O([KO26^94OZ2Z>_.(3O><_4$L#!!0
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M:   #@              @ $     9#(S,3@Q-F0X:RYH=&U02P$"% ,4
M" !/2613 DJU6NX:   <PP  $0              @ '/#P  9#(S,3@Q-F1E
M>#DY,2YH=&U02P$"% ,4    " !/26132O7NU,T7   I7P  $0
M    @ 'L*@  9#(S,3@Q-F1E>#DY,BYH=&U02P$"% ,4    " !/2613CS-1
MYTT#  !]"P  $0              @ 'H0@  ;6=T82TR,#(Q,3$P-"YX<V10
M2P$"% ,4    " !/2613^"_]KXX&   Y1P  %0              @ %D1@
M;6=T82TR,#(Q,3$P-%]L86(N>&UL4$L! A0#%     @ 3TED4Z/>#TS3!
MSBP  !4              ( !)4T  &UG=&$M,C R,3$Q,#1?<')E+GAM;%!+
4!08     !@ & '\!   K4@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
